Alternatives to amyloid for Alzheimer's disease therapies—a symposium report
For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid-targeting therapies; however, with one possible exception, none of these therapies have been effective in preventing or delaying cognitive...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021
|
| Online Access: | https://hdl.handle.net/1721.1/129349 |
| _version_ | 1811092765963976704 |
|---|---|
| author | Cable, Jennifer Holtzman, David M. Hyman, Bradley T. Tansey, Malú Gámez Colonna, Marco Kellis, Manolis Brinton, Roberta D. Albert, Marilyn Wellington, Cheryl L. Sisodia, Sangram S. Tanzi, Rudolph E. |
| author2 | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory |
| author_facet | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory Cable, Jennifer Holtzman, David M. Hyman, Bradley T. Tansey, Malú Gámez Colonna, Marco Kellis, Manolis Brinton, Roberta D. Albert, Marilyn Wellington, Cheryl L. Sisodia, Sangram S. Tanzi, Rudolph E. |
| author_sort | Cable, Jennifer |
| collection | MIT |
| description | For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid-targeting therapies; however, with one possible exception, none of these therapies have been effective in preventing or delaying cognitive decline in patients, and there are no approved disease-modifying agents. It is becoming more apparent that alternative drug targets are needed to address this complex disease. An increased understanding of Alzheimer's disease pathology has highlighted the need to target the appropriate disease pathology at the appropriate time in the disease course. Preclinical and early clinical studies have focused on targets, including inflammation, tau, vascular health, and the microbiome. This report summarizes the presentations from a New York Academy of Sciences' one-day symposium entitled “Alzheimer's Disease Therapeutics: Alternatives to Amyloid,” held on November 20, 2019. |
| first_indexed | 2024-09-23T15:25:05Z |
| format | Article |
| id | mit-1721.1/129349 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T15:25:05Z |
| publishDate | 2021 |
| publisher | Wiley |
| record_format | dspace |
| spelling | mit-1721.1/1293492022-09-29T14:39:58Z Alternatives to amyloid for Alzheimer's disease therapies—a symposium report Cable, Jennifer Holtzman, David M. Hyman, Bradley T. Tansey, Malú Gámez Colonna, Marco Kellis, Manolis Brinton, Roberta D. Albert, Marilyn Wellington, Cheryl L. Sisodia, Sangram S. Tanzi, Rudolph E. Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid-targeting therapies; however, with one possible exception, none of these therapies have been effective in preventing or delaying cognitive decline in patients, and there are no approved disease-modifying agents. It is becoming more apparent that alternative drug targets are needed to address this complex disease. An increased understanding of Alzheimer's disease pathology has highlighted the need to target the appropriate disease pathology at the appropriate time in the disease course. Preclinical and early clinical studies have focused on targets, including inflammation, tau, vascular health, and the microbiome. This report summarizes the presentations from a New York Academy of Sciences' one-day symposium entitled “Alzheimer's Disease Therapeutics: Alternatives to Amyloid,” held on November 20, 2019. 2021-01-08T16:31:56Z 2021-01-08T16:31:56Z 2020-05 2020-04 2021-01-05T19:17:55Z Article http://purl.org/eprint/type/JournalArticle 0077-8923 1749-6632 https://hdl.handle.net/1721.1/129349 Cable, Jennifer et al. "Alternatives to amyloid for Alzheimer's disease therapies—a symposium report." Annals of the New York Academy of Sciences 1475, 1 (May 2020): 3-14 © 2020 New York Academy of Sciences en http://dx.doi.org/10.1111/nyas.14371 Annals of the New York Academy of Sciences Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Wiley MIT web domain |
| spellingShingle | Cable, Jennifer Holtzman, David M. Hyman, Bradley T. Tansey, Malú Gámez Colonna, Marco Kellis, Manolis Brinton, Roberta D. Albert, Marilyn Wellington, Cheryl L. Sisodia, Sangram S. Tanzi, Rudolph E. Alternatives to amyloid for Alzheimer's disease therapies—a symposium report |
| title | Alternatives to amyloid for Alzheimer's disease therapies—a symposium report |
| title_full | Alternatives to amyloid for Alzheimer's disease therapies—a symposium report |
| title_fullStr | Alternatives to amyloid for Alzheimer's disease therapies—a symposium report |
| title_full_unstemmed | Alternatives to amyloid for Alzheimer's disease therapies—a symposium report |
| title_short | Alternatives to amyloid for Alzheimer's disease therapies—a symposium report |
| title_sort | alternatives to amyloid for alzheimer s disease therapies a symposium report |
| url | https://hdl.handle.net/1721.1/129349 |
| work_keys_str_mv | AT cablejennifer alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT holtzmandavidm alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT hymanbradleyt alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT tanseymalugamez alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT colonnamarco alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT kellismanolis alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT brintonrobertad alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT albertmarilyn alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT wellingtoncheryll alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT sisodiasangrams alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport AT tanzirudolphe alternativestoamyloidforalzheimersdiseasetherapiesasymposiumreport |